What is the best size descriptor to use for pharmacokinetic studies in the obese?

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 119-133

  Green, Bruce ^a,b   Duffull, Stephen B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Body mass index; Body surface area; Body weight; Obesity; Pharmacokinetics

Indexed keywords

BODY FAT; BODY MASS; BODY SIZE; BODY SURFACE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG CLEARANCE; HUMAN; INDIVIDUALITY; LEAN BODY WEIGHT; LIPOPHILICITY; MEDICAL LITERATURE; OBESITY; PHARMACOKINETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW;

ANTI-OBESITY AGENTS; BODY MASS INDEX; BODY SURFACE AREA; BODY WEIGHT; HUMANS; OBESITY;

EID: 3843141820     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02157.x     Document Type: Review

References (81)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
2. National Institute of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, MD: US Department of Health and Human Services, 1998.
3. Lurbe E, Alvarez V, Redon J. Obesity, body fat distribution, and ambulatory blood pressure in children and adolescents. J Clin Hypertens 2001; 3: 362-7.
4. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9: 326S-334S.
5. World Health Organization. Report of a WHO Consultation on Obesity: Preventing and Managing the Global Epidemic. Geneva: WHO, 1998.
6. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1-7.
7. Anastasio P, Spitali L, Frangiosa A et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000; 35: 1144-8.
8. Nowack R, Raum E, Blum W, Ritz E. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992; 20: 342-7.
9. Cockroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Duffull S, Dooley M, Green B, Poole S, Kirkpatrick C. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; in press.
11. Kjellberg J, Reizenstein P. Body composition in obesity. Acta Med Scandanavia 1970; 188: 161-9.
12. Cheymol G. Clinical pharmacokietics of drugs in obesity. Clin Pharmacokinet 1993; 25: 103-14.
13. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet 2000; 39: 215-31.
14. Quetelet LAJ, eds. Physique Sociale vol 2. Brussels, C. Muquardt, 1869: 92.
15. Keys A, Fidanza F, Karvonen M, Kimura N, Taylor H. Indices of relative weight and obesity. J Chronic Dis 1972; 25: 329-43.
16. Morse W, Soeldner JS. The composition of adipose tissue and the nonadipose body of obese and nonobese man. Metabolism 1963; 12: 99-107.
17. Du Bois D, Du Bois EF. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863.
18. Meeh K., Oberflächenmessungen des menschlichen körpers. Ztschr f Biol, München, 1879; 15: 425-58.
19. Mosteller RD. Simplified calculation of body surfaced area. N Eng J Med 1987; 317: 1098.
20. Dooley M, Singh S, Poole S, Toner G, Michael M. Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancy. The utility of BMI to identify obese patients and its implications in BSA adjusted dosing of cytotoxics. Proc Am Soc Clin Oncol 2002; 21: 356.
21. Turcotte G. Erroneous nomograms for body-surface area. N Eng J Med 1979; 300: 1339.
22. Ideal Weights for Women. Stat Bull Metropolitan Life Insurance Co October 1942.
23. Ideal Weights for Men. Stat Bull Metropolitan Life Insurance Co June 1943.
24. New Weight Standards for Men and Women. Stat Bull Metropolitan Life Insurance Co Nov-Dec 1959; 40: 1-4.
25. Mortality among overweight men and women. Stat Bull Metropolitan Life Insurance Co 1960; 41: 6.
26. Society of Actuaries. Build and Blood Pressure Study. New York; Peter Mallon, 1959.
27. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr 1977; 1: 11-22.
28. Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-5.
29. Rathbun EN, Pace N. The determination of total body fat by means of the body specific gravity. J Biol Chem 1945; 158: 667-76.
30. Hume R, Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 1971; 24: 234-8.
31. Durnin JVGA, Rahaman MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 1967; 21: 681-9.
32. Boddy K, King PC, Hume R, Weyers E. Estimation of the fat-free mass of twenty subjects from measurements of total body potassium, body density, skinfold thickness, and height and weight. Proc Nutr Soc 1972; 31: 35A.
33. Lukaski HC, Bolonchuk WW, Hall CB, Siders WA. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol 1986; 60: 1327-32.
34. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. Am J Clin Nutr 1988; 47: 7-14.
35. Gray DS, Bray GA, Gemayel N, Kaplan K. Effect of obesity on bioelectrical impedance. Am J Clin Nutr 1989; 50: 255-60.
36. 2) as a measure of fatness. Int J Obes 1985; 9: 147-53.
37. Jaber LA, Antal EJ, Slaughter RL, Welshman IR. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Eur J Clin Pharmacol 1993; 45: 459-63.
38. James W. Research on Obesity. London: Her Majesty's Stationery Office, 1976.
39. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Clin Pharmacokinet 1994; 26: 292-307.
40. Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743-4.
41. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643-7.
42. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-7.
43. Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity. Drug Intell Clin Pharm 1983; 17: 516-22.
44. Kowalski KC, Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the liklihood ratio test. J Pharmacokinet Pharmacodynam 2001; 28: 253-75.
45. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-28.
46. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994; 22: 165-77.
47. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. MPS Pharm Sci 2002; 4: 27.
48. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001; 28: 231-52.
49. Boddy K, King PC, Hume R, Weyers E. The relationship of total body potassium to height, weight and age in normal subjects. J Clin Pathol 1972; 25: 512-7.
50. Womersley J, Boddy K, King PC, Durnin JVGA. A comparison of the fat free mass of young adults estimated by anthropometry, body density and total potassium content. Clin Sci 1972; 43: 469-75.
51. Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 1994; 55: 392-8.
52. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol 2000; 56: 293-7.
53. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
54. Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93: 4436-40.
55. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-5.
56. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 1989; 25: 139-42.
57. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord 1995; 19: 234-9.
58. Davis RL, Quenzer RW, Bozigian HP, Warner CW. Pharmacokinetics of ranitidine in morbidly obese women. Drug Intell Clin Pharm 1990; 24: 1040-3.
59. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 1995; 29: 843-7.
60. Bauer LA, Blouin RA, Griffen WO Jr, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980; 37: 519-22.
61. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
62. Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72: 308-18.
63. Green B, Duffull S. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2002; 56: 96-103.
64. Blouin RA, Mann HJ, Griffen WO Jr, Bauer LA, Record KE. Tobramydn pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979; 26: 508-612.
65. Benezet S, Guimbaud R, Chatelut E, Chevreau C, Bugat R, Canal P. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 1997; 8: 607-9.
66. Barrett JS, Gibiansky E, Hull RD et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001; 39: 431-46.
67. Egan TD, Huizinga B, Gupta SK et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-73.
68. Kinowski JM, Rodier M, Bressolle F et al. Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy. J Pharm Sci 1995; 84: 307-11.
69. Jermain DM, Crismon ML, Martin ES 3rd. Population pharmacokinetics of lithium. Clin Pharm 1991; 10: 376-81.
70. Fisher D, Schoolar Reynolds K, Schmith VD et al. The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium. Anesth Analg 1999; 89: 789-95.
71. Nguyen L, Tranchand B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002; 53: 459-68.
72. Nguyen L, Chatelut E, Chevreau C et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998; 41: 125-32.
73. Slepchenko G, Simon N, Goubaux B, Levron JC, Le Moing JP, Raucoules-Aime M. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology 2003; 98: 65-73.
74. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazoiam and triazolam. Clin Pharmacokinet 1984; 9: 177-83.
75. Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986; 21: 529-32.
76. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995; 39: 684-7.
77. Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 1991; 41: 171-4.
78. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-77.
79. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci 1982; 71: 942-4.
80. Rizzo A, Mirabella A, Bonanno A. Effect of body weight on the volume of distribution of theophylline. Lung 1988; 166: 269-76.
81. Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol 1985; 42: 468-71.